EICHORCondition: Chronic Spontaneous Urticaria · Sponsor: Evommune, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Cahaba Dermatology Skin Health Center | Birmingham, Alabama, United States | — |
| Velocity Clinical Research, Mobile | Mobile, Alabama, United States | — |
| Center for Dermatology Clinical Research | Fremont, California, United States | — |
| Antelope Valley Clinical Trials | Lancaster, California, United States | — |
| Northridge Clinical Trials | Northridge, California, United States | — |
| NorthBay Clinical Research | Santa Rosa, California, United States | — |
| Integrated Research of Inland | Upland, California, United States | — |
| FOMAT Medical Research | Ventura, California, United States | — |
| AMR Fort Myers | Fort Myers, Florida, United States | — |
| Advanced Clinical Research Institute | Tampa, Florida, United States | — |
| Sneeze, Wheeze & Itch Associates LLC | Normal, Illinois, United States | — |
| The Indiana Clinical Trials Center | Plainfield, Indiana, United States | — |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06873516